Garren believes diabetes to be a market just as large as that for cancer.
FORBES: Beware Of Biotechs At Cancer-Cure Prices
2.
"There are real products in late-stage trials producing real results, " observes Dr. Ron Garren, an oncologist in California and editor of Biotech Insight.
FORBES: Beware Of Biotechs At Cancer-Cure Prices
3.
"I wouldn't buy it here, but I wouldn't short it either, " says Garren, noting the extremes to which biotechs can go on the upside and the downside.